ANGPTL3

ANGPTL3, a liver-expressed protein encoded and regulated by the LXR, is a key player in lipid metabolism. By inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL), ANGPTL3 reduces the hydrolysis of triglycerides in chylomicrons and VLDL, leading to lower levels of LDL-C, VLDL-C, HDL-C, and triglycerides. This protein's inhibitory effect is pivotal for blood lipid regulation and cardiovascular risk reduction. Linked to a decreased risk of atherosclerotic cardiovascular disease, ANGPTL3 is highlighted by studies showing that individuals with loss-of-function mutations in ANGPTL3 have reduced lipid levels and coronary heart disease incidence. As a result, ANGPTL3 has become a target for lipid-lowering therapies, with clinical trials of drugs like Evinacumab and Vupanorsen showing potential in reducing blood lipid levels. In essence, ANGPTL3's role in lipid metabolism renders it a significant target in the quest for novel treatments to mitigate cardiovascular diseases.